101079-84-9

Basic information

• Product Name: 4-Chloro-1-(chloromethyl)-2-methoxybenzene
• Synonyms: 4-chloro-1-(chloromethyl)-2-methoxybenzene;101079-84-9;4-chloro-2-methoxybenzyl chloride;Anisole, 5-chloro-2-(chloromethyl)-;4-chloro-2-methoxy benzyl chloride;SCHEMBL2152147;DZNWZPDQZJANKH-UHFFFAOYSA-N;DTXSID201267158;BEA07984;AKOS010993954;FT-0747704;EN300-1968311
• CAS NO: 101079-84-9
• Molecular Weight: 191.057
• Mol File: 101079-84-9.mol

Chemical Properties

• CAS DataBase Reference: 4-Chloro-1-(chloromethyl)-2-methoxybenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-1-(chloromethyl)-2-methoxybenzene(101079-84-9)
• EPA Substance Registry System: 4-Chloro-1-(chloromethyl)-2-methoxybenzene(101079-84-9)

Safety Data

• Hazardous Substances Data: 101079-84-9(Hazardous Substances Data)

Upstream product

• 78955-90-5 methyl 4-chloro-2-methoxybenzoate 
• 57479-70-6 2-methoxy-4-chlorobenzoic acid 
• 90296-27-8 (4-chloro-2-methoxy-phenyl)methanol 

Downstream Products

• 896127-80-3 (4-chloro-2-methoxyphenyl)methanamine 
• 896127-79-0 1-(azidomethyl)-4-chloro-2-methoxybenzene 
• 170737-92-5 (4-chloro-2-methoxyphenyl)acetonitrile 
• 888739-78-4 3-[1-(4-chloro-2-methoxybenzyl)-3-isopropoxy-1H-pyrazole-5-yl]propanoic acid ethyl ester 

Relevant articles and documents

SUBSTITUTED 2,4 DIAMINO-QUINOLINE AS NEW MEDICAMENT FOR FIBROSIS, AUTOPHAGY AND CATHEPSINS B (CTSB), L (CTSL) AND D (CTSD) RELATED DISEASES

The present invention relates to novel 2-primary amino-4-secondary amino-quinoline derivatives, their manufacture, pharmaceutical compositions comprising them and their use as medicaments. The active compounds of the present invention can be useful as a medicament in the treatment and/or the decreasing and/or the prevention of fibrosis and/or fibrosis related diseases, or for use as a medicament in the treatment and/or the decreasing and/or the prevention of the autophagy and/or autophagy related diseases and for the inhibition of the autophagy flux, or for use in the inhibition of cathepsins B (CTSB), L (CTSL) and/or D (CTSD) and/or cathepsins B (CTSB), L (CTSL) and/or D (CTSD) related diseases; with the proviso that said compounds are not to be used for the treatment of any forms of cancers.

SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof : (I) in which m, n, W, X, Y, Z, R1, R2, R3 and R4 are as defined in the specification, for use in the treatm

ARYLALKANOIC ACID DERIVATIVE

A compound represented by the formula (I): wherein Ar is an optionally substituted aromatic ring; Xa, Xc, Ya, Yc, Z1 and Z2 are each a bond, O, S, -CO-, -CS-, - CR3 (OR4) -, -NR5-, -SO-, -SO2-, -CONR6- or -NR6CO- (wherein R3, R4, R5 and R6 are as defined in the specification); Xb and Yb are each a bond or a divalent hydrocarbon group having 1 to 20 carbon atoms; R1 is an optionally substituted hydrocarbon group; ring A is an optionally further substituted aromatic ring, provided that the ring should not be benzimidazole; n is an integer of 1 to 8; ring B is an optionally further substituted aromatic ring, provided that the ring should not be oxazole; W is a divalent saturated hydrocarbon group having 1 to 20 carbon atoms; and R2 is -OR8 or -NR9R10 (wherein R8, R9 and R10 are as defined in the specification) or a salt thereof, is useful as an agent for the prophylaxis or treatment of diabetes and the like.

HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY

Compounds of formula I depicted below, pharmaceutical compositions containing them, processes for preparing the compounds, and their use in the treatment of obesity, type II diabetes, metabolic syndrome, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy and related conditions, neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease, and pain related disorders. The compounds are melanin concentrating hormone receptor 1 (MCHr1) antagonists.

SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES

The invention relates to substituted acids of formula (I), where T,W,X,Y,Z, R1 and R2 as defined in the claims, as useful pharmaceutical compounds for treating asthma and rhinitis, pharmaceutical compositions containing them, and a processes for their preparation.

ARYLALKANOIC ACID DERIVATIVE

A compound represented by the general formula (I): [wherein Ar represents an optionally substituted aromatic ring; Xa, Xc, Ya, Yc, Z1, and Z2 each represents a bond, O, S, -CO-, -CS-, -CR3(OR4)-, -NR5-, -SO-, -SO2-, -CONR6-, or -NR6CO- (R3, R4, R5, and R6 are as defined in the description); Xb and Yb each represents a bond or a C1-20 divalent hydrocarbon group; R1 represents an optionally substituted hydrocarbon group; ring A represents an aromatic ring (other than benzimidazole) which may be further substituted; n is an integer of 1-8; ring B represents an aromatic ring (other than oxazole) which may be further substituted; W represents a C1-20 divalent saturated hydrocarbon group; and R2 represents -OR8 or -NR9R10 (R8, R9, and R10 are as defined in the description)] or a salt of the compound. It is useful as a preventive/therapeutic agent for diabetes, etc.